论文部分内容阅读
目的从细胞水平对乳腺癌耐药机制进行探讨 ,以期为选择化疗方案提供参考 ,获得更有效的化疗效果。方法应用免疫组化S_P法 ,对乳腺癌的主要耐药指标GST_π、TOPOⅡ进行检测 ,并结合临床分期进行研究。结果乳腺癌中GST_π的表达为63.6 %(28/44) ,临床Ⅲ期表达显著高于临床Ⅰ、Ⅱ期。TOPOⅡ表达为47.7 %(21/44) ,临床Ⅲ期表达显著低于Ⅰ、Ⅱ期。TOPOⅡ与GST_π表达关系间无明显相关性 ,说明它们各自的表达从不同方面对肿瘤耐药起作用。结论在乳腺癌化疗药物选择时 ,通过联合检测GST_π、TOPOⅡ的表达具有指导作用 ,对判断预后有参考价值。
Objective To investigate the mechanism of drug resistance of breast cancer cells at the cellular level in order to provide a reference for the selection of chemotherapy regimens and to obtain more effective chemotherapy effects. Methods Immunohistochemical S_P method was used to detect GST_π and TOPOⅡ, the major resistance markers of breast cancer, and to study the clinical staging. Results The expression of GST_π in breast cancer was 63.6% (28/44), the expression in stage Ⅲ was significantly higher than that in stage Ⅰ and Ⅱ. The expression of TOPOⅡwas 47.7% (21/44), and the expression in stage Ⅲ was significantly lower than that in stage Ⅰ and Ⅱ. There was no significant correlation between TOPO Ⅱ and GST_π expression, indicating that their respective expressions play a role in tumor drug resistance in different aspects. Conclusions In the selection of chemotherapy drugs for breast cancer, the combination of GST_π and TOPO Ⅱ can guide the prognosis.